Clinical trial
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
NCT00089713 · Synvista Therapeutics, Inc, Industry · Terminated
Key facts
| NCT number | NCT00089713 |
|---|---|
| Title | Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA) |
| Official title | Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients |
| Lead sponsor | Synvista Therapeutics, Inc, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | alagebrium chloride (ALT-711) |
| Enrollment | 392 |
| Start date | Mar 1, 2004 |
| First posted | Aug 12, 2004 |
| Last update posted | Feb 8, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: